Reclassifying marijuana as a less dangerous drug might only be the first step for Trump
Federal cannabis reclassification to Schedule III represents a landmark shift in medical cannabis policy with significant clinical implications. This regulatory change acknowledges cannabis's therapeutic potential while creating new pathways for research…
DOJ Schedule III cannabis order creates uncertainty for D.C.’s medical self-certification program
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyMedical CannabisFederal…
Federal marijuana rescheduling could trigger obscure SC law – Post and Courier
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyMedical CannabisFederal…
Adriana E. Ramírez: Trump Administration gets it right on weed – Pittsburgh Post-Gazette
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyFederal SchedulingMedical…
Bridging the Regulatory Chasm in Investigator‐Initiated Human Subject Cannabis Research
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Research BarriersRegulatory…